Phase 2 Program in Pediatric Classic Congenital Adrenal Hyperplasia (CAH) on Track to Initiate in 2021 with Data Expected by 1H 2023 Phase 3 Registrational Program in Pediatric Classic CAH Expected to ...
SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback